Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - COGENTIX MEDICAL INC /DE/ex99-1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 7, 2011
 
Vision-Sciences, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
0-20970
13-3430173
(State or other jurisdiction of incorporation)
(Commission file number)
(IRS employer identification no.)
     

40 Ramland Road South
Orangeburg, NY
10962
(Address of principal executive offices)
(Zip code)
   
Registrant's telephone number, including area code: (845) 365-0600
 
 

(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[  ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14[a-12)
[  ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
Item 2.02. Results of Operations and Financial Condition.
 
On November 7, 2011, the Company issued an earnings release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
 
 
Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1    Press release dated November 7, 2011 announcing financial results for the three and six months ended September 30, 2011.
 
The information in this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 
 
2

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, Vision-Sciences, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
VISION-SCIENCES, INC.
     
     
 
By:
/s/ Cynthia Ansari
   
Name:
Cynthia Ansari
   
Title:
Chief Executive Officer
       
 
Date:  November 7, 2011
 
3